Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Sold by Capital Fund Management S.A.

Capital Fund Management S.A. reduced its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 18.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 22,458 shares of the biotechnology company’s stock after selling 5,111 shares during the period. Capital Fund Management S.A.’s holdings in Aurinia Pharmaceuticals were worth $202,000 at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the company. Invesco Ltd. lifted its stake in Aurinia Pharmaceuticals by 1.0% in the fourth quarter. Invesco Ltd. now owns 144,112 shares of the biotechnology company’s stock valued at $1,294,000 after buying an additional 1,421 shares during the last quarter. Teacher Retirement System of Texas boosted its stake in Aurinia Pharmaceuticals by 5.9% during the 4th quarter. Teacher Retirement System of Texas now owns 36,098 shares of the biotechnology company’s stock worth $324,000 after purchasing an additional 2,020 shares during the period. SBI Securities Co. Ltd. purchased a new position in Aurinia Pharmaceuticals during the 4th quarter worth $25,000. China Universal Asset Management Co. Ltd. increased its stake in Aurinia Pharmaceuticals by 10.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 30,359 shares of the biotechnology company’s stock valued at $273,000 after purchasing an additional 2,857 shares during the period. Finally, FMR LLC raised its holdings in shares of Aurinia Pharmaceuticals by 44.8% in the third quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock valued at $93,000 after buying an additional 3,919 shares during the last quarter. 36.83% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, StockNews.com upgraded Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, March 27th.

Insider Transactions at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, CFO Joseph M. Miller sold 61,859 shares of the firm’s stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $8.00, for a total value of $494,872.00. Following the completion of the sale, the chief financial officer now owns 633,515 shares of the company’s stock, valued at approximately $5,068,120. This trade represents a 8.90 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Greg Keenan sold 8,305 shares of the company’s stock in a transaction on Friday, March 7th. The stock was sold at an average price of $8.23, for a total transaction of $68,350.15. Following the transaction, the insider now directly owns 153,484 shares in the company, valued at approximately $1,263,173.32. This trade represents a 5.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 343,898 shares of company stock worth $2,753,094. Company insiders own 4.30% of the company’s stock.

Aurinia Pharmaceuticals Price Performance

Shares of NASDAQ AUPH opened at $7.67 on Thursday. The stock has a fifty day moving average price of $7.99 and a 200 day moving average price of $8.09. Aurinia Pharmaceuticals Inc. has a 1-year low of $4.71 and a 1-year high of $10.67. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11. The company has a market cap of $1.05 billion, a PE ratio of -51.13 and a beta of 1.20.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.